Last reviewed · How we verify
Myfortic plus low-dose steroid
Myfortic plus low-dose steroid is a Immunosuppressant (inosine monophosphate dehydrogenase inhibitor) Small molecule drug developed by The University of Hong Kong. It is currently FDA-approved for Organ transplant rejection prevention (renal, cardiac, hepatic transplantation). Also known as: Mycophenolate sodium.
Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection, while the steroid provides additional anti-inflammatory effects.
Myfortic (mycophenolate sodium) combined with low-dose corticosteroids suppresses T and B lymphocyte proliferation to prevent organ rejection in transplant recipients. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.
At a glance
| Generic name | Myfortic plus low-dose steroid |
|---|---|
| Also known as | Mycophenolate sodium |
| Sponsor | The University of Hong Kong |
| Drug class | Immunosuppressant (inosine monophosphate dehydrogenase inhibitor) |
| Target | Inosine monophosphate dehydrogenase (IMPDH), type II |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate sodium is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for guanine nucleotide synthesis in lymphocytes. This preferentially depletes guanine nucleotides in T and B cells, inhibiting their proliferation. The addition of low-dose corticosteroids enhances immunosuppression through glucocorticoid receptor-mediated suppression of cytokine production and immune cell activation.
Approved indications
- Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, abdominal pain)
- Infection (bacterial, viral, fungal)
- Leukopenia
- Anemia
- Hypertension
- Hyperglycemia
- Tremor, headache
Key clinical trials
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (PHASE3)
- A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf (NA)
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Myfortic plus low-dose steroid CI brief — competitive landscape report
- Myfortic plus low-dose steroid updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI
Frequently asked questions about Myfortic plus low-dose steroid
What is Myfortic plus low-dose steroid?
How does Myfortic plus low-dose steroid work?
What is Myfortic plus low-dose steroid used for?
Who makes Myfortic plus low-dose steroid?
Is Myfortic plus low-dose steroid also known as anything else?
What drug class is Myfortic plus low-dose steroid in?
What development phase is Myfortic plus low-dose steroid in?
What are the side effects of Myfortic plus low-dose steroid?
What does Myfortic plus low-dose steroid target?
Related
- Drug class: All Immunosuppressant (inosine monophosphate dehydrogenase inhibitor) drugs
- Target: All drugs targeting Inosine monophosphate dehydrogenase (IMPDH), type II
- Manufacturer: The University of Hong Kong — full pipeline
- Therapeutic area: All drugs in Immunology / Transplantation
- Indication: Drugs for Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)
- Also known as: Mycophenolate sodium
- Compare: Myfortic plus low-dose steroid vs similar drugs
- Pricing: Myfortic plus low-dose steroid cost, discount & access